JP7551499B2 - Ｆｃバリアント組成物およびその使用方法 - Google Patents

Ｆｃバリアント組成物およびその使用方法 Download PDF

Info

Publication number
JP7551499B2
JP7551499B2 JP2020550791A JP2020550791A JP7551499B2 JP 7551499 B2 JP7551499 B2 JP 7551499B2 JP 2020550791 A JP2020550791 A JP 2020550791A JP 2020550791 A JP2020550791 A JP 2020550791A JP 7551499 B2 JP7551499 B2 JP 7551499B2
Authority
JP
Japan
Prior art keywords
amino acid
antibody
polypeptide
kabat
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518411A (ja
Inventor
ウェイン エー． マラスコ
クアン カレン ジュー
マシュー アール． チャン
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2021518411A publication Critical patent/JP2021518411A/ja
Priority to JP2024049655A priority Critical patent/JP7804715B2/ja
Application granted granted Critical
Publication of JP7551499B2 publication Critical patent/JP7551499B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020550791A 2018-03-21 2019-03-21 Ｆｃバリアント組成物およびその使用方法 Active JP7551499B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024049655A JP7804715B2 (ja) 2018-03-21 2024-03-26 Ｆｃバリアント組成物およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646053P 2018-03-21 2018-03-21
US62/646,053 2018-03-21
PCT/US2019/023382 WO2019183362A1 (en) 2018-03-21 2019-03-21 Fc variant compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024049655A Division JP7804715B2 (ja) 2018-03-21 2024-03-26 Ｆｃバリアント組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2021518411A JP2021518411A (ja) 2021-08-02
JP7551499B2 true JP7551499B2 (ja) 2024-09-17

Family

ID=67988040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550791A Active JP7551499B2 (ja) 2018-03-21 2019-03-21 Ｆｃバリアント組成物およびその使用方法
JP2024049655A Active JP7804715B2 (ja) 2018-03-21 2024-03-26 Ｆｃバリアント組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024049655A Active JP7804715B2 (ja) 2018-03-21 2024-03-26 Ｆｃバリアント組成物およびその使用方法

Country Status (5)

Country Link
US (2) US20210070860A1 (OSRAM)
EP (1) EP3768315A4 (OSRAM)
JP (2) JP7551499B2 (OSRAM)
AU (2) AU2019240247B2 (OSRAM)
WO (1) WO2019183362A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN120309734A (zh) 2021-01-13 2025-07-15 威特拉公司 人源化补体5a受体1抗体和其使用方法
CN113061192B (zh) * 2021-04-12 2023-08-22 佰思巢(上海)生物科技有限公司 一类对pd-1受体具有高亲和力的pdl1融合蛋白及其作为t细胞抑制剂的应用
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
AU2023324667A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512019A (ja) 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
US20130295085A1 (en) 2011-04-04 2013-11-07 Randolph J. Noelle ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY
WO2013165690A1 (en) 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2016033509A1 (en) 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
WO2016139365A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
WO2011076922A1 (en) 2009-12-23 2011-06-30 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
AU2012214643B2 (en) * 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
JP5997151B2 (ja) * 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
CA2959772A1 (en) 2014-09-12 2016-03-17 Biogen Ma Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
WO2016120218A1 (en) * 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
KR102534568B1 (ko) * 2016-07-22 2023-05-18 다나-파버 캔서 인스티튜트 인크. 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
CN109963871A (zh) * 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512019A (ja) 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
US20130295085A1 (en) 2011-04-04 2013-11-07 Randolph J. Noelle ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY
WO2013165690A1 (en) 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2016033509A1 (en) 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
WO2016139365A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use

Also Published As

Publication number Publication date
AU2019240247B2 (en) 2026-01-29
WO2019183362A1 (en) 2019-09-26
EP3768315A1 (en) 2021-01-27
JP2024081718A (ja) 2024-06-18
JP2021518411A (ja) 2021-08-02
AU2019240247A1 (en) 2020-10-15
EP3768315A4 (en) 2022-11-30
US20250066481A1 (en) 2025-02-27
JP7804715B2 (ja) 2026-01-22
US20210070860A1 (en) 2021-03-11
AU2026203163A1 (en) 2026-05-14

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
US20250066481A1 (en) Fc variant compositions and methods of use thereof
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
JP2022065039A (ja) マクロファージ上のＦｃ受容体結合の破壊による抗ＳｌＲＰα抗体療法の効果増強
JP2020511997A (ja) 腫瘍抗原提示誘導物質構築物及びその使用
JP7261307B2 (ja) 新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
CN119143873A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
CN116323665A (zh) 抗cd200r1抗体及其使用方法
JP2025534285A (ja) プロテアーゼ活性化ポリペプチド
CN120882748A (zh) 多特异性抗体及其用途
WO2023138638A1 (zh) 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途
KR20240116828A (ko) 이중 mhc-표적화 t 세포 관여자
US20240376205A1 (en) Targeted interferon alpha fusion proteins and methods of use
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
WO2025049915A1 (en) Ilt2 binding agents and uses thereof
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
CN117715934A (zh) 抗cd3构建体及其用途
HK40114235A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40114510A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
TW202602924A (zh) 抗ccr8抗體之醫藥配製物
CN121219321A (zh) 与bcma特异性结合的免疫刺激性抗原结合分子
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230530

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240904

R150 Certificate of patent or registration of utility model

Ref document number: 7551499

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150